New evidence underscores TumorSight® Viz’s ability to deliver reproducible landmark identification and measurement for early-stage breast cancer surgical planning CHICAGO, IL – March 5, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today…